ChemGenex Pharmaceuticals Receives European Allowance For Cancer Drug Patent
ChemGenex Pharmaceuticals has received notice of allowance for a European patent covering the use of its drug Quinamed® (amonafide dihydrochloride) as a drug to boost the effect of existing cancer therapies.
MELBOURNE, Australia, and MENLO PARK, California U.S.A
February 17, 2005
Quinamed® - currently in Phase II trials for the treatment of prostate cancer in the U.S. - has been shown in studies to improve the effects of current chemotherapeutics drugs.
ChemGenex today announced that it received a Notice of Allowance from the European Patent Office (EPO) for its patent application entitled "Compositions Containing Naphthalimide and an Antiproliferative Agent." This patent will cover compositions and methods of use of the company's investigational agent, amonafide dihydrochloride (Quinamed®), to improve or "chemopotentiate" the anti-cancer effects of common chemotherapeutics, including cisplatin, paclitaxel, vinblastine and camptothecin.
Quinamed® is currently undergoing Phase II human clinical testing as a potential treatment for hormone refractory prostate cancer. Although currently approved antiproliferative agents offer therapeutic activity against many forms of cancers, improvements in tumor response rates, duration of response and ultimately patient survival are still sought for these agents. ChemGenex researchers have determined that naphthalimides and analogs of the class of compounds, including Quinamed®, can potentiate the antitumor effects of chemotherapeutic drugs, in particular, agents affecting the integrity of nucleic acids such as DNA.
"ChemGenex has filed numerous patents covering amonafide compositions, formulations, synthesis and uses," said Greg Collier, Ph.D., chief executive officer of ChemGenex. "This initial patent will provide protection for the longer term use of Quinamed® in conjunction with other agents. Other patent applications cover the composition of matter for amonafide dihydrochloride, and for a variety of other amonafide salts created with organic acids."
Quinamed is a novel naphthalimide analog currently in Phase II clinical trials for hormone refractory prostate cancer.
ChemGenex Pharmaceuticals is a gene-based pharmaceutical company dedicated to improving the lives of patients by developing therapeutics in the areas of oncology, diabetes, obesity, and depression. ChemGenex currently has two compounds in Phase II clinical trials, Ceflatonin® for leukemia and Quinamed® for solid tumors, and has a significant portfolio of anti-cancer, diabetes, obesity and depression programs. The company's diabetes and obesity program is partnered with Merck KGaA and the depression program is partnered with Vernalis. ChemGenex currently trades on the Australian Stock Exchange under the symbol "CXS".
| Dr. Greg Collier (CEO and Managing Director) |
Australia +61 3 5227 2752
USA +1 650 474 9800 ext 103 |
| Dr. Dennis Brown (President and Director) |
USA +1 650 474 9800 ext 108
Australia +61 3 5227 2703 |
Certain statements made herein that use the words "estimate," 'project," "intend," "expect," "believe," and similar expressions are intended to identify forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties which could cause the actual results, performance or achievements of the company to be materially different from those which may be expressed or implied by such statements, including, among others, risks or uncertainties associated with the development of the company's technology, the ability to successfully market products in the clinical pipeline, the ability to advance promising therapeutics through clinical trials, the ability to establish our fully integrated technologies, the ability to enter into additional collaborations and strategic alliances and expand current collaborations and obtain milestone payments, the suitability of internally discovered genes for drug development , the ability of the company to meet its financial requirements, the ability of the company to protect its proprietary technology, potential limitations on the company's technology, the market for the company's products, government regulation in Australia and the United States, changes in tax and other laws, changes in competition and the loss of key personnel. These statements are based on our management's current expectations and are subject to a number of uncertainties that could change the results described in the forward-looking statements. Investors should be aware that there are no assurances that results will not differ from those projected.
